Pasar al contenido principal

TEJIDO ADIPOSO EPICARDICO EN OBESIDAD Y DIABETES. MECANISMOS MOLECULARES DE RIESGO CARDIOVASCULAR Y BUSQUEDA DE NUEVOS BIOMARCADORES.

PI20/00334

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins

  • Reis, Ana|||0000-0002-4537-9902
  • Rocha, Sara
  • Dias, Irundika HK.|||0000-0002-6620-8221
  • Costa, Raquel|||0000-0002-9245-4565
  • Soares, Raquel|||0000-0002-9157-5541
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
  • de Freitas, Victor|||0000-0003-0586-2278
The incidence of diabetes on the worldwide population has tripled in the past 5 decades. While drug-based therapies are valuable strategies to treat and ease the socio-economic burden of diabetes, nutritional strategies offer valuable alternatives to prevent and manage diabetes onset and contribute to the sustainability of health budgets. Whilst, intervention studies have shown that (poly)phenol-rich diets improve fasting glucose levels and other blood parameters, very little is known about the distribution of ingested polyphenols in circulation and the impact of diabetes on its cargo. In this study we investigate the impact of type 2 diabetes on the cargo of plasma (poly)phenols. Our results show that phenolic compounds are heterogeneously distributed in circulation though mainly transported by lipoprotein populations. We also found that diabetes has a marked effect on the phenolic content transported by VLDL resulting in the decrease in the content of flavonoids and consequently a decrease in the antioxidant capacity. In addition to the reduced bioavailability of (poly)phenol metabolites and increase of oxidative status in LDL and HDL populations in diabetes, cell-based assays show that sub-micromolar amounts of microbial (poly)phenol metabolites are able to counteract the pro-inflammatory status in glucose-challenged endothelial cells. Our findings highlight the relevance of triglyceride-rich lipoproteins in the transport and delivery of bioactive plant-based compounds to the endothelium in T2DM supporting the adoption of nutritional guidelines as an alternative strategy to drug-based therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein J protects cardiomyocytes from lipid-mediated inflammation and cytotoxicity induced by the epicardial adipose tissue of diabetic patients

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Gil Millán, Pedro
  • Miñambres, Inka|||0000-0002-0899-3938
  • Ginel, Antonino|||0000-0002-8820-7545
  • Tauron, Manel|||0000-0002-5864-519X
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Diabetic patients present increased volume and functional alterations in epicardial adipose tissue (EAT). We aimed to analyze EAT from type 2 diabetic patients and the inflammatory and cytotoxic effects induced on cardiomyocytes. Furthermore, we analyzed the cardioprotective role of apolipoprotein J (apoJ). EAT explants were obtained from nondiabetic patients (ND), diabetic patients without coronary disease (DM), and DM patients with coronary disease (DM-C) after heart surgery. Morphological characteristics and gene expression were evaluated. Explants were cultured for 24 h and the content of nonesterified fatty acids (NEFA) and sphingolipid species in secretomes was evaluated by lipidomic analysis. Afterwards, secretomes were added to AC16 human cardiomyocytes for 24 h in the presence or absence of cardioprotective molecules (apoJ and HDL). Cytokine release and apoptosis/necrosis were assessed by ELISA and flow cytometry. The EAT from the diabetic samples showed altered expression of genes related to lipid accumulation, insulin resistance, and inflammation. The secretomes from the DM samples presented an increased ratio of pro/antiatherogenic ceramide (Cer) species, while those from DM-C contained the highest concentration of saturated NEFA. DM and DM-C secretomes promoted inflammation and cytotoxicity on AC16 cardiomyocytes. Exogenous Cer16:0, Cer24:1, and palmitic acid reproduced deleterious effects in AC16 cells. These effects were attenuated by exogenous apoJ. Diabetic secretomes promoted inflammation and cytotoxicity in cardiomyocytes. This effect was exacerbated in the secretomes of the DM-C samples. The increased content of specific NEFA and ceramide species seems to play a key role in inducing such deleterious effects, which are attenuated by apoJ.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Atherogenic circulating lipoproteins in ischemic stroke

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The fundamental role of qualitative alterations of lipoproteins in the early development of atherosclerosis has been widely demonstrated. Modified low-density lipoproteins (LDL), such as oxidized LDL (oxLDL), small dense LDL (sdLDL), and electronegative LDL [LDL(-)], are capable of triggering the atherogenic process, favoring the subendothelial accumulation of cholesterol and promoting inflammatory, proliferative, and apoptotic processes characteristic of atherosclerotic lesions. In contrast, high-density lipoprotein (HDL) prevents and/or reverses these atherogenic effects. However, LDL's atherogenic and HDL's anti-atherogenic actions may result altered in certain pathological conditions. The molecular mechanisms underlying the impaired effects of altered lipoproteins have been studied in numerous in vitro and in vivo studies, and have been extensively analyzed in coronary atherosclerosis, especially in the context of pathologies such as dyslipidemia, diabetes, obesity, and metabolic syndrome. However, the corresponding studies are scarcer in the field of ischemic stroke, despite carotid arteriosclerosis progression underlies at least 20% of ischemic strokes. The present review relates qualitative alterations of LDL and HDL with the development of carotid arteriosclerosis and the occurrence of ischemic stroke.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Epicardial Adipose Tissue with Novel Inflammation and Heart Failure Biomarkers in Type 2 Diabetes Patients, Effect of Metabolic Control

  • Gil, Pedro|||0000-0003-3707-7450
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Background : Type 2 diabetes (T2D patients) have a 74% increased risk of heart failure (HF), but traditional HF biomarkers lack sensitivity in early disease detection. Increased epicardial adipose tissue volume (EATv) is associated with cardiovascular risk in T2D, and novel biomarkers such as growth differentiation factor 15 (GDF15), Galectin-3, and soluble suppression of tumorigenicity 2 (sST2) are inflammation biomarkers linked to HF. Methods : We investigated associations between EATv, inflammation biomarkers, and the effect of metabolic control in 14 healthy controls (HCs) and 36 newly diagnosed T2D patients both before (poor glycemic control, PGC) and after 12 months of glycemic optimization (good glycemic control, GGC). EATv indexed to body surface area (iEATv) was quantified by multidetector computed tomography, and biomarker levels were measured by immunoassays. Results : PGC patients had higher iEATv (59.53 ± 21.67 vs. 36.84 ± 16.57 cm 3 /m 2, p = 0.0017) and elevated GDF15, Galectin-3, and sST2 levels (all p < 0.05) than HC subjects. The glycemic optimization reduced iEATv (p = 0.0232) and sST2 (p = 0.048), while GDF15 and Galectin-3 remained unchanged. Multivariable analysis confirmed independent associations between iEATv, GDF15 (β = 0.27, p = 0.027) and sST2 (β = 0.29, p = 0.02). Conclusions : These results support the link between systemic inflammation, EAT expansion, and cardiac dysfunction, and they point to the role of epicardial fat in early HF risk of T2D patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-Density Lipoprotein Subfraction Phenotype Is Associated with Epicardial Adipose Tissue Volume in Type 2 Diabetes

  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Gil, Pedro|||0000-0003-3707-7450
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Background : Increased epicardial adipose tissue (EAT) volume is a common feature in type 2 diabetes (T2DM) which is directly associated with heart failure and advanced atherosclerosis. We aimed to evaluate lipoprotein-related biomarkers of EAT volume in T2DM patients before and after glycemic control. Methods : This study included 36 T2DM patients before and after optimization of glycemic control and on 14 healthy controls (HCs). EAT volume was measured using computed tomography imaging indexed to the body surface area (iEAT). Biochemical and lipid profiles were determined using commercial methods. Lipoproteins were isolated by ultracentrifugation, and variables of lipoprotein function were assessed. Multivariable regression analysis was used to find variables independently associated with iEAT. Results : iEAT was higher in T2DM than in controls and decreased with glycemic optimization. HDLs from T2DM had less apoA-I and cholesterol and more apoC-III and triglycerides. LDLs from T2DM had more triglycerides and apoB and smaller sizes than those from HCs. Significant correlations were found between iEAT and age, BMI, HbA1c, GGT, VLDLc, triglycerides, LDL size, apoA-I in HDL, and apoC-III in HDL. In the multivariable regression analysis, age, LDL size, and GGT associations remained statistically significant, and predicted 50% of the variability in EAT volume. ROC analysis using these variables showed an AUC of 0.835. Conclusions : Qualitative characteristics of lipoproteins were altered in T2DM. Multivariable analysis showed that LDL size and GGT plasma levels were independently associated with iEAT volume, suggesting that these variables might be useful biomarkers for stratifying T2DM patients with increased EAT volume.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alterations in LDL and HDL after an ischemic stroke associated with carotid atherosclerosis are reversed after 1 year

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Hermansson, M.
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Bautista, Olga
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Blanco Sanroman, Nerea|||0009-0003-4653-0170
  • Domine, María Constanza
  • Öörni, K.|||0000-0002-9525-0250
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Approximately, 20% of ischemic strokes are attributed to the presence of atherosclerosis. Lipoproteins play a crucial role in the development of atherosclerosis, with LDL promoting atherogenesis and HDL inhibiting it. Therefore, both their concentrations and their biological properties are decisive factors in atherosclerotic processes. In this study, we examined the qualitative properties of lipoproteins in ischemic stroke patients with carotid atherosclerosis. Lipoproteins were isolated from the blood of healthy controls (n ¼ 27) and patients with carotid atherosclerosis (n ¼ 64) at 7 days and 1 year postischemic stroke. Compared to controls, patients' LDL 7 days poststroke showed increased levels of apoC-III, triacylglycerol, and ceramide, along with decreased cholesterol and phospholipid content. LDL from patients induced more inflammation in macrophages than did LDL from controls. HDL isolated from patients 7 days after stroke showed alterations in the apolipoprotein cargo, with reduced levels of apoA-I and increased levels of apoA-II, and apoC-III compared to controls. Patients' HDL also showed a higher electronegative charge than that of controls and partially lost its ability to counteract the modification of LDL and the inflammatory effects of modified LDL. One year after stroke onset, the composition of patients' LDL and HDL resembled those of the controls. In parallel, LDL and HDL gained positive charge, LDL became less prone to oxidation and aggregation, and HDL regained protective properties. In conclusion, LDL and HDL in ischemic stroke patients with carotid atherosclerosis exhibited alterations in composition and function, which were partially reversed 1 year after stroke.(Figure Presented).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epicardial Fat and Heart Failure in Type 2 Diabetes, Metabolism, Imaging and Novel Biomarkers-A Translational Perspective

  • Gil, Pedro|||0000-0003-3707-7450
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Heart failure (HF) is a major cardiovascular complication in people with type 2 diabetes (T2D), where heart failure with preserved ejection fraction (HFpEF) is the most common presentation. Despite its high prevalence, HF in T2D often remains undiagnosed during its early stages due to nonspecific symptoms and the limitations of conventional diagnostic tools. Epicardial adipose tissue (EAT), a visceral fat depot surrounding the myocardium, has emerged as a mechanistic and clinically relevant contributor to myocardial dysfunction. In T2D, EAT expansion fosters a pro-inflammatory, fibrotic, and metabolically adverse milieu that may directly promote the onset and progression of HF. This perspective synthesizes current translational evidence on the role of EAT in the pathogenesis of HF among individuals with T2D. We highlight diagnostic challenges related to imaging-based quantification and the limited sensitivity of natriuretic peptide-based screening, while emphasizing the potential relevance of emerging biomarkers such as GDF-15, Galectin-3, sST2, LDL particle size, GGT, and soluble low-density lipoprotein receptor-related protein 1 (sLRP1) to enhance early detection and risk stratification. Additionally, therapeutic approaches-including lifestyle modification, SGLT2 inhibitors, and GLP-1 receptor agonists-are considered for their potential to modulate EAT volume and reduce cardiovascular risk. Advancing knowledge on EAT biology and its circulating biomarkers holds promise to refine HF risk stratification and support translational efforts toward precision cardiometabolic care.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered small dense LDL profiles in long-standing controlled Type 1 Diabetes

  • Sardà, Helena|||0000-0002-0138-8217
  • Solé, Arnau|||0009-0007-6517-6188
  • Colom, Cristina|||0000-0002-2926-4697
  • Borràs, Carla|||0000-0002-0998-7855
  • Carreras, Gemma|||0000-0002-6718-8381
  • Benitez, Sonia|||0000-0003-3565-0743
  • Miñambres, Inka|||0000-0002-0899-3938
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Introduction: Small dense low-density lipoprotein (sdLDL) is a highly atherogenic LDL subclass associated with cardiovascular disease (CVD). While type 1 diabetes confers increased cardiovascular risk despite adequate glycemic control, the role of sdLDL and its regulators remains unclear. Methods: In this cross-sectional observational study, plasma from individuals with long-standing type 1 diabetes and 24 healthy controls was analyzed. sdLDL-cholesterol (sdLDL-C) concentration, sdLDL-C/LDL-cholesterol ratio, LDL size and subclasses were assessed using homogeneous assays, NMR spectroscopy, and gradient gel electrophoresis. Apolipoprotein C3 (ApoC3), hepatic lipase (HL), endothelial lipase (EL), and cholesteryl ester transfer protein (CETP) activity were measured by immunoturbidimetric, ELISA and functional assays. Results: Despite adequate glycemic control (mean HbA1c 7.6% [60 mmol/mol]) and near-normal lipid levels, individuals with type 1 diabetes had significantly higher sdLDL-C (0.56 ± 0.28 mmol/L vs 0.43 ± 0.26 mmol/L), increased sdLDL-C/LDL-cholesterol ratio (0.20 ± 0.08 vs 0.12 ± 0.06) and smaller LDL particle size (26.32 ± 1.08 nm vs 26.81 ± 0.68 nm) compared with controls. ApoC3 and HL mass/activity were significantly increased (8.67 ± 3.22 mg/dL vs 6.53 ± 2.42; 46.60 ± 16.12 ng/mL vs 15.45 ± 7.40 ng/mL and 1.03 ± 0.24 U/mL vs 0.89 ± 0.23 U/mL; respectively), CETP activity significantly reduced (808.8 ± 197.0 pmol/mL/h vs 929.7 ± 149.6 pmol/mL/h), and endothelial lipase levels unchanged. sdLDL-C positively correlated with ApoC3 (r = 0.7517) and inversely with CETP activity (r = -0.2682). Conclusion: Long-standing type 1 diabetes with adequate glycemic control is associated with an atherogenic sdLDL profile despite near-normal conventional lipid levels. This first multi-method characterization study of sdLDL in type 1 diabetes highlights the contribution of ApoC3, CETP and HL to sdLDL-C enrichment and suggests that direct assessment of sdLDL may improve cardiovascular risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electronegative LDL Is Associated with Plaque Vulnerability in Patients with Ischemic Stroke and Carotid Atherosclerosis

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Solé, Arnau|||0009-0007-6517-6188
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Casoni, Francesca
  • Pérez, Belén|||0000-0001-5801-1704
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Owing to the high risk of recurrence, identifying indicators of carotid plaque vulnerability in atherothrombotic ischemic stroke is essential. In this study, we aimed to identify modified LDLs and antioxidant enzymes associated with plaque vulnerability in plasma from patients with a recent ischemic stroke and carotid atherosclerosis. Patients underwent an ultrasound, a CT-angiography, and an 18 F-FDG PET. A blood sample was obtained from patients (n = 64, 57.8% with stenosis ≥50%) and healthy controls (n = 24). Compared to the controls, patients showed lower levels of total cholesterol, LDL cholesterol, HDL cholesterol, apolipoprotein B (apoB), apoA-I, apoA-II, and apoE, and higher levels of apoJ. Patients showed lower platelet-activating factor acetylhydrolase (PAF-AH) and paraoxonase-1 (PON-1) enzymatic activities in HDL, and higher plasma levels of oxidized LDL (oxLDL) and electronegative LDL (LDL(-)). The only difference between patients with stenosis ≥50% and <50% was the proportion of LDL(-). In a multivariable logistic regression analysis, the levels of LDL(-), but not of oxLDL, were independently associated with the degree of carotid stenosis (OR: 5.40, CI: 1.15-25.44, p < 0.033), the presence of hypoechoic plaque (OR: 7.52, CI: 1.26-44.83, p < 0.027), and of diffuse neovessels (OR: 10.77, CI: 1.21-95.93, p < 0.033), indicating that an increased proportion of LDL(-) is associated with vulnerable atherosclerotic plaque.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Presence of Ceramidase Activity in Electronegative LDL

  • Puig Calvó, Núria|||0000-0001-8235-4934
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Estruch, Montserrat|||0000-0002-7162-4158
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Colomé, Núria
  • Canals, Francesc|||0000-0002-0650-1135
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL(-)) is a minor modified fraction of human plasma LDL with several atherogenic properties. Among them is increased bioactive lipid mediator content, such as lysophosphatidylcholine (LPC), non-esterified fatty acids (NEFA), ceramide (Cer), and sphingosine (Sph), which are related to the presence of some phospholipolytic activities, including platelet-activating factor acetylhydrolase (PAF-AH), phospholipase C (PLC), and sphingomyelinase (SMase), in LDL(-). However, these enzymes' activities do not explain the increased Sph content, which typically derives from Cer degradation. In the present study, we analyzed the putative presence of ceramidase (CDase) activity, which could explain the increased Sph content. Thin layer chromatography (TLC) and lipidomic analysis showed that Cer, Sph, and NEFA spontaneously increased in LDL(-) incubated alone at 37 °C, in contrast with native LDL(+). An inhibitor of neutral CDase prevented the formation of Sph and, in turn, increased Cer content in LDL(-). In addition, LDL(-) efficiently degraded fluorescently labeled Cer (NBD-Cer) to form Sph and NEFA. These observations defend the existence of the CDase-like activity's association with LDL(-). However, neither the proteomic analysis nor the Western blot detected the presence of an enzyme with known CDase activity. Further studies are thus warranted to define the origin of the CDase-like activity detected in LDL(-).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Can Electronegative LDL Act as a Multienzymatic Complex?

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Solé, Arnau|||0009-0007-6517-6188
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy

  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Vert, Carla
  • Rovira, Alex|||0000-0002-2132-6750
  • Freijo, M. Mar
  • Tur, Silvia
  • Martínez-Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Domínguez-Mayoral, Ana
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Mauri, Gerard
  • Montaner, Joan|||0000-0003-4845-2279
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of amyloid-β (Aβ) in brain vessels and is a main cause of lobar intracerebral hemorrhage (ICH) in the elderly. CAA is associated with magnetic resonance imaging (MRI) markers of small vessel disease (SVD). Since Aβ is also accumulated in Alzheimer's disease (AD) in the brain parenchyma, we aimed to study if several single nucleotide polymorphisms (SNPs) previously associated with AD were also associated with CAA pathology. Furthermore, we also studied the influence of APOE and CLU genetic variants in apolipoprotein E (ApoE) and clusterin/apolipoprotein J (ApoJ) circulating levels and their distribution among lipoproteins. The study was carried out in a multicentric cohort of 126 patients with lobar ICH and clinical suspicion of CAA. We observed several SNPs associated with CAA neuroimaging MRI markers [cortical superficial siderosis (cSS), enlarged perivascular spaces in the centrum semiovale (CSO-EPVS), lobar cerebral microbleeds (CMB), white matter hyperintensities (WMH), corticosubcortical atrophy and CAA-SVD burden score]. Concretely, ABCA7 (rs3764650), CLU (rs9331896 and rs933188), EPHA1 (rs11767557), and TREML2 (rs3747742) were significantly associated with a CAA-SVD burden score. Regarding circulating levels of apolipoproteins, protective AD SNPs of CLU [rs11136000 (T) and rs9331896 (C)] were significantly associated with higher HDL ApoJ content in the lobar ICH cohort. APOEε2 carriers presented higher plasma and LDL-associated ApoE levels whereas APOEε4 carriers presented lower plasma ApoE levels. Additionally, we observed that lower circulating ApoJ and ApoE levels were significantly associated with CAA-related MRI markers. More specifically, lower LDL-associated ApoJ and plasma and HDL-associated ApoE levels were significantly associated with CSO-EPVS, lower ApoJ content in HDL with brain atrophy and lower ApoE content in LDL with the extent of cSS. This study reinforces the relevance of lipid metabolism in CAA and cerebrovascular functionality. We propose that ApoJ and ApoE distribution among lipoproteins may be associated with pathological features related to CAA with higher ApoE and ApoJ levels in HDL possibly enhancing atheroprotective, antioxidative, and anti-inflammatory responses in cerebral β-amyloidosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obesity Surgery Improves Hypogonadism and Sexual Function in Men without Effects in Sperm Quality

  • Miñambres, Inka|||0000-0002-0899-3938
  • Sardà, Helena|||0000-0002-0138-8217
  • Urgell, Eulàlia|||0000-0003-3519-1022
  • Genua, Idoia|||0000-0001-6834-561X
  • Ramos Rodas, Analia Emilce|||0000-0002-0882-1247
  • Fernández-Ananín, Sonia|||0000-0002-5068-1954
  • Balagué Ponz, Carmen|||0000-0003-2429-8297
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Bassas, Lluís|||0000-0002-3473-3611
  • Pérez, Antonio|||0000-0001-5528-1143
Obesity is associated with hypogonadism, sexual dysfunction, and impaired fertility in men. However, its effects on semen parameters or sexual function remain debatable. This paper involves a longitudinal study in men submitted for obesity surgery at a university tertiary hospital. Patients were studied at baseline and at 6, 12, and 18 months after obesity surgery. At each visit, anthropometry measures were collected and hormonal and semen parameters were studied. Sexual function was evaluated with the International Index of Erectile Function (IIEF). A total of 12 patients were included. The average body mass index of patients decreased from 42.37 ± 4.44 to 29.6 ± 3.77 kg/m 2 at 18 months after surgery (p < 0.05). Hormonal parameters improved after obesity surgery. The proportion of sperm cells with normal morphology tended to decrease from baseline and became most significant at 18 months (5.83 ± 4.50 vs. 2.82 ± 2.08). No significant changes were found in the remaining semen parameters. Erectile function improved significantly at six months after surgery. The authors believe that, in general, the effects of obesity surgery on fertility may be limited or even deleterious (at least in the short and midterm follow-up).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PCSK9 plasma concentration is associated with epicardial adipose tissue volume and metabolic control in patients with type 1 diabetes

  • Sardà, Helena|||0000-0002-0138-8217
  • Colom, Cristina|||0000-0002-2926-4697
  • Benitez, Sonia|||0000-0003-3565-0743
  • Carreras, Gemma|||0000-0002-6718-8381
  • Amigó, Judit|||0000-0003-2407-1906
  • Miñambres, Inka|||0000-0002-0899-3938
  • Viladés Medel, David|||0000-0002-3638-9703
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Patients with type 1 diabetes (T1D) have a greater risk of cardiovascular disease. Proconvertase subtilisin-kexin 9 (PCSK9) is involved in the atherosclerosis process. This study aimed to determine the relationship between PCSK9 levels and epicardial adipose tissue (EAT) volume and cardiometabolic variables in patients with T1D. This was an observational cross-sectional study including 73 patients with T1D. Clinical, biochemical and imaging data were collected. We divided the patients into two groups according to their glycemic control and the EAT index (iEAT) percentile. We performed a correlation analysis between the collected variables and PCSK9 levels; subsequently, we performed a multiple regression analysis with the significant parameters. The mean age was 47.6 ± 8.5 years, 58.9% were men, and the BMI was 26.9 ± 4.6 kg/m 2. A total of 31.5%, 49.3% and 34.2% of patients had hypertension, dyslipidemia and smoking habit, respectively. The PCSK9 concentration was 0.37 ± 0.12 mg/L, which was greater in patients with worse glycemic control (HbA1c.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro|||0000-0003-3707-7450
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garcia-Moll, Xavier|||0000-0001-7837-8378
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez, Antonio|||0000-0001-5528-1143
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efectos cardiometabólicos de la pérdida de peso, Cardiometabolic effects of weight loss

  • Genua, Idoia|||0000-0001-6834-561X
  • Sardà, Helena|||0000-0002-0138-8217
  • Pérez, Antonio|||0000-0001-5528-1143
La prevalencia de sobrepeso y obesidad y, en consecuencia, de las comorbilidades relacionadas, está incrementándose de forma muy significativa a nivel mundial. Las guías recomiendan pérdidas de peso de.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LDL binding to cell receptors and extracellular matrix is proatherogenic in obesity but improves after bariatric surgery

  • Jayaraman, Shobini|||0000-0003-1616-5347
  • Pérez, Antonio|||0000-0001-5528-1143
  • Miñambres, Inka|||0000-0002-0899-3938
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gursky, Olga
Obesity is a major global public health issue involving dyslipidemia, oxidative stress, inflammation, and increased risk of CVD. Weight loss reduces this risk, but the biochemical underpinnings are unclear. We explored how obesity and weight loss after bariatric surgery influence LDL interactions that trigger proatherogenic versus anti-atherogenic processes. LDL was isolated from plasma of six patients with severe obesity before (basal) and 6-12 months after bariatric surgery (basal BMI ¼ 42.7 kg/m; 6-months and 12-months postoperative BMI ¼ 34.1 and 30 kg/m). Control LDL were from six healthy subjects (BMI ¼ 22.6 kg/m). LDL binding was quantified by ELISA; LDL size and charge were assessed by chromatography; LDL biochemical composition was determined. Compared to controls, basal LDL showed decreased nonatherogenic binding to LDL receptor, which improved postoperatively. Conversely, basal LDL showed increased binding to scavenger receptors LOX1 and CD36 and to glycosaminoglycans, fibronectin and collagen, which is proatherogenic. One year postoperatively, this binding decreased but remained elevated, consistent with elevated lipid peroxidation. Serum amyloid A and nonesterified fatty acids were elevated in basal and postoperative LDL, indicating obesity-associated inflammation. Aggregated and electronegative LDL remained elevated, suggesting proatherogenic processes. These results suggest that obesity-induced inflammation contributes to harmful LDL alterations that probably increase the risk of CVD. We conclude that in obesity, LDL interactions with cell receptors and extracellular matrix shift in a proatherogenic manner but are partially reversed upon postoperative weight loss. These results help explain why the risk of CVD increases in obesity but decreases upon weight loss.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido|||0000-0003-1454-0916
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Crespo García, Javier|||0000-0001-8248-0172
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16-5p, miR-142-3p, miR-223-3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335-3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221-3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter.